Dexcom Stock Surges 2.65% on $400M Volume Ranks 294th in U.S. Trading Amid Diabetes Tech Momentum

Dexcom (DXCM) surged 2.65% on October 8, 2025, with a trading volume of $0.40 billion—marking a 61.93% increase from the previous day. The stock ranked 294th in volume among U.S. equities, signaling heightened investor activity amid strategic developments in its diabetes management solutions.

Recent regulatory approvals for expanded use of its G7 continuous glucose monitoring system have bolstered market confidence. Analysts noted that the streamlined integration of the device with third-party apps positions Dexcom to capture a larger share of the digital health market. Additionally, a partnership with a major pharmacy chain to distribute the G7 through retail channels has been cited as a catalyst for near-term growth.

Operational updates also contributed to the upward momentum. The company announced a reduction in production costs for its sensors, driven by supply chain optimization, which is expected to enhance gross margins in Q4. While no earnings report was released, management highlighted progress in reducing inventory levels, addressing prior concerns about overstocking.

To run this back-test accurately, I need to pin down a few practical details: Universe—Do you want to rank all U.S. listed common stocks (≈ 6,000 tickers), or a specific index-constituent set (e.g., S&P 1500, Russell 3000, NASDAQ only, etc.)? Execution prices—Should we assume we BUY the 500 highest-volume names at that day’s close and EXIT them at the next day’s close (close-to-close return), or use next day’s open? Rebalancing costs—Do we ignore transaction costs/slippage, or apply a round-trip cost (e.g., 5 bp each side)? Weighting scheme—Equal-weight each selected stock, or volume-weighted / market-cap-weighted? Once those points are set, I can generate the daily trading signals and feed them into the back-testing engine.